found that multiple myeloma patients with low SNRPB2 expression had better prognoses, and inhibiting SNRPB2 increased the sensitivity of multiple myeloma to treatment with ixazomib (25). The gene discussed is SNRPB2; the disease is plasma cell myeloma.